Pemetrexed (Pem), carboplatin (Cb), and bevacizumab (Bev) in patients with nonsquamous NSCLC without or with activating EGFR mutation (CJLSG0909/0910).

Tomoki Kimura,Hiroyuki Taniguchi,Tomohiko Ogasawara,Masashi Kondo,Ryujiro Suzuki,Masashi Yamamoto,J. Shindo,Osamu Hataji,Norio Yoshida,Eiji Kojima,Yoshinori Hasegawa,Hiroshi Saito

Pemetrexed (Pem), carboplatin (Cb), and bevacizumab (Bev) in patients with nonsquamous NSCLC without or with activating EGFR mutation (CJLSG0909/0910).

2015

Tomoki Kimura
Hiroyuki Taniguchi
Tomohiko Ogasawara
Masashi Kondo
Ryujiro Suzuki
Masashi Yamamoto
J. Shindo
Osamu Hataji
Norio Yoshida
Eiji Kojima
Yoshinori Hasegawa
Hiroshi Saito

e19038 Background: Treatment strategies for advanced non-squamous (sq) non-small cell lung cancer (NSCLC) are divided by EGFR mutations. However, there has been no previous report about efficacy of...

Keywords:

Pemetrexed
Carboplatin
Pathology
Oncology
Bevacizumab
Internal medicine
Medicine
Activating EGFR Mutation
egfr mutation
treatment strategy
in patient
non small cell

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations